Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services

Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services

Abstract Within 2 years after the start of the coronavirus disease 2019 (COVID-19) pandemic, novel severe acute respiratory syndrome coronavirus 2 vaccines were developed, rigorously evaluated in large phase 3 trials, and administered to more than 5 billion individuals globally. However, adverse eve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2022-08, Vol.75 (Supplement_1), p.S11-S17
Hauptverfasser: Top, Karina A, Chen, Robert T, Levy, Ofer, Ozonoff, Al, Carleton, Bruce, Crawford, Nigel W, Creech, C Buddy, Kochhar, Sonali, Poland, Gregory A, Gutu, Kimberley, Cutland, Clare L
Format: Artikel
Sprache:eng
Schlagworte:
BNT162 Vaccine
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Humans
Immunization
Myocarditis
Pandemics - prevention & control
Precision Vaccines Supplement
RNA, Messenger
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Within 2 years after the start of the coronavirus disease 2019 (COVID-19) pandemic, novel severe acute respiratory syndrome coronavirus 2 vaccines were developed, rigorously evaluated in large phase 3 trials, and administered to more than 5 billion individuals globally. However, adverse events of special interest (AESIs) have been described post-implementation, including myocarditis after receipt of messenger RNA (mRNA) vaccines and thrombosis with thrombocytopenia syndrome after receipt of adenoviral vector vaccines. AESIs are rare (
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciac407